Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Expands By 33.1%

Posted by Donna Armstrong on Jan 31st, 2025

vTv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 22,500 shares, an increase of 33.1% from the December 31st total of 16,900 shares. Currently, 1.5% of the shares of the company are short sold. Based on an average daily trading volume, of 29,400 shares, the days-to-cover ratio is presently 0.8 days.

Institutional Investors Weigh In On vTv Therapeutics

A hedge fund recently bought a new stake in vTv Therapeutics stock. FMR LLC acquired a new stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT – Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 178,200 shares of the biotechnology company’s stock, valued at approximately $2,402,000. FMR LLC owned about 5.92% of vTv Therapeutics at the end of the most recent quarter. 17.51% of the stock is currently owned by institutional investors.

vTv Therapeutics Trading Up 2.9 %

Shares of VTVT opened at $14.66 on Friday. The business’s 50-day moving average price is $14.73 and its 200-day moving average price is $15.19. vTv Therapeutics has a twelve month low of $8.03 and a twelve month high of $30.99.

vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.88) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Alliance Global Partners started coverage on shares of vTv Therapeutics in a report on Monday, December 9th. They set a “buy” rating and a $35.00 price objective for the company.

View Our Latest Research Report on VTVT

vTv Therapeutics Company Profile

(Get Free Report)

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.